ArticleJournal of Cancer2025

Isoliquiritigenin inhibits colorectal cancer progression by targeting the FGFR4/FASN mediated lipid metabolism pathway.

Xiaohui Zhai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.